{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-011309","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.935929+00:00","generated_at":"2026-05-23T19:08:18.538050+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Clene: 96% of CNM-Au8-treated MS patients with vision gains also showed MRI remyelination evidence","bullets":["96% of LCLA visual responders had improved MRI DTI metrics (AD/MTR), confirming remyelination and neuronal repair.","91% of LCLA visual responders showed multi-focal VEP improvements (latency/amplitude), indicating functional recovery.","98% of SDMT cognitive responders exhibited corresponding MRI DTI improvements, linking cognitive gains to repair.","Data from long-term open-label extension of Phase 2 VISIONARY-MS trial presented at AAN 2025 Late-Breaking Science Session.","Clene plans to confirm findings in a global Phase 3 trial for CNM-Au8 in multiple sclerosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-011309","json":"https://secwatch.observer/filing/0001437749-25-011309.json","markdown":"https://secwatch.observer/filing/0001437749-25-011309.md","text":"https://secwatch.observer/filing/0001437749-25-011309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774925011309/0001437749-25-011309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774925011309/clnn20250407_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:08:18.538050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}